What is Immuno Laboratories?
Immuno Laboratories operates at the intersection of personalized medicine and consumer health, specializing in advanced food sensitivity diagnostics. The company is best known for its proprietary Bloodprint panels, which utilize IgG antibody reactivity metrics to identify specific dietary and environmental triggers. By providing comprehensive IgE and trigger-specific panels, the firm enables a data-driven approach to wellness, allowing clients to optimize their dietary habits through precise, laboratory-verified insights. Their commitment to expedited, high-accuracy results has established them as a key player in the growing market for direct-to-consumer health diagnostics.
How much funding has Immuno Laboratories raised?
Immuno Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Immuno Laboratories
PPP
Public-Private Partnership
What's next for Immuno Laboratories?
With the completion of this late-stage funding, Immuno Laboratories is expected to pivot toward aggressive market expansion and technological refinement. The strategic allocation of this capital will likely focus on increasing laboratory throughput, expanding the reach of their Bloodprint diagnostic suite, and potentially integrating advanced digital health platforms to improve patient engagement. As the demand for personalized nutrition and preventative health monitoring continues to rise, the company is strategically aligned to capture a larger share of the diagnostic testing market, moving beyond traditional clinical channels to reach a broader, health-conscious consumer base.
See full Immuno Laboratories company page
